{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22","value":"156"}]}],"title":"Week 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"181"}]}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"205"}]}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"221"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22","value":"228"}]}],"title":"Week 18"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"}],"units":"Participants"}],"description":"PK Cmax of Ramucirumab Blood samples were collected at specified time points, and in the event of an infusion-related reaction, for assessment of ramucirumab serum concentrations.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"8 mg/kg ramucirumab administered as an IV injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + BSC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Weeks 0, 2, 6, 12 and 18, Day 1; 1 hour to 1.5 hours Post End of Infusion (14 day-Cycles)","title":"PK: Serum Concentration Maximum (Cmax) After 1st, 2nd, 4th, 7th and 10th Ram Infusion","type":"SECONDARY","unitOfMeasure":"ng/mL"}